CDA Data Reveals Trends on Drug Approvals and Reimbursements in Canada

Why It Matters

The data reveals faster regulatory assessments but longer payer negotiations, reshaping launch timing and market‑access strategies for pharma companies in Canada.

Key Takeaways

• Drug approvals dropped 26% from 2020 to 2024.
• Pre‑NOC HTA submissions doubled, post‑NOC submissions fell.
• Positive CDA recommendations rose to 94%, all with conditions.
• Median HTA review 206 days; reimbursement lag reached 967 days.

Pulse Analysis

The CDA’s newly published dataset offers a rare longitudinal view of Canada’s drug approval and health‑technology‑assessment (HTA) landscape. While the total number of Health Canada approvals has been on a downward trajectory—150 in 2020 to 111 in 2024—the proportion of those drugs entering the CDA reimbursement pipeline remains steady at just under half. Notably, manufacturers are shifting toward pre‑Notice of Compliance (pre‑NOC) submissions, which more than doubled over the five‑year span, reflecting a strategic move to secure pricing and coverage decisions earlier in the product lifecycle.

Faster HTA processing is another headline. The median time from submission to final recommendation fell from 235 days in 2020 to 206 days in 2024, and 92% of reviews now meet the 180‑day draft‑recommendation target. At the same time, CDA’s recommendation profile has become more favorable: positive outcomes rose to 94% and now uniformly include clinical criteria or price‑reduction conditions. The introduction of time‑limited reimbursement pathways for rare or severe diseases adds a new lever for manufacturers to gain early market access while gathering additional data.

For pharmaceutical firms, the juxtaposition of quicker HTA decisions with a lengthening overall reimbursement timeline—now averaging 967 days from approval to public‑plan listing—highlights the growing complexity of post‑HTA negotiations with the pan‑Canadian Pharmaceutical Alliance and provincial payers. Companies must align global launch plans with these extended payer cycles, allocate commercial resources to sustain market presence during protracted negotiations, and consider early pre‑NOC engagement to mitigate delays. Leveraging the CDA data can sharpen forecasting, optimize supply‑chain timing, and improve pricing strategies in a market where regulatory transparency is finally catching up with commercial realities.